NCT05604131View on ClinicalTrials.gov

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2029

Conditions
Acute Myocardial Infarction Type 1
Interventions
DRUG

Deferiprone Tablets

Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.

DRUG

Placebo

Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.

Trial Locations (1)

46202

RECRUITING

Krannert Cardiovascular Research Center, Indianapolis

All Listed Sponsors
lead

Rohan Dharmakumar

OTHER